查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2024940

癌症和腫瘤分析市場規模、佔有率、趨勢和預測：按癌症類型、技術、方法、應用和地區分類，2026-2034 年

Cancer/Tumor Profiling Market Size, Share, Trends, and Forecast by Cancer Type, Technology, Technique, Application, and Region, 2026-2034
出版日期: | 出版商: IMARC | 英文 144 Pages | 商品交期: 2-3個工作天內

價格

2025年全球癌症和腫瘤分析市場規模為135億美元。展望未來，IMARC Group預測，到2034年，該市場規模將達到273億美元，2026年至2034年的複合年成長率（CAGR）為7.89%。目前，北美市場佔據主導地位，預計到2025年將佔據超過42.8%的市場。精準醫療的進步、癌症發病率的上升以及個人化治療方案的日益普及，正推動著該市場取得顯著成長。除了對基於生物標記的診斷需求不斷成長外，基因組學和蛋白​​質組學分析技術的創新也進一步促進了市場擴張。

癌症和腫瘤分析市場的發展主要得益於基因組學和蛋白​​質組學技術的進步，這些技術能夠實現精準的分子診斷。全球癌症發生率的上升，以及對個人化醫療需求的不斷成長，正在加速癌症和腫瘤分析市場的成長。例如，2024年12月，Aster DM Healthcare在Aster癌症大會上宣布推出三項舉措－精準腫瘤診所（Precision Oncology Clinics）、Aster癌症網格（Aster Cancer Grid）和Onco Collect。這些計畫旨在透過基因組學方法加強數據驅動的個人化癌症治療，促進合作研究，並改善患者預後，從而將印度打造成為創新癌症治療領域的領導者。政府和私人對腫瘤研究的投入也發揮著至關重要的作用。新一代定序（NGS）和生物標記發現技術正被擴大應用於早期檢測和標靶治療，而液態生物檢體的創新則提高了分析的準確性，並推動了市場擴張。

美國癌症和腫瘤分析市場的發展主要受高癌症發病率和日益成長的個人化醫療需求的驅動。根據美國國家醫學圖書館發布的數據，預計到2024年，美國將新增約2,001,140例癌症病例，並有611,720例死亡病例。基因組學和蛋白​​質組學技術的進步，例如新一代定序（NGS），正在提高腫瘤分析的準確性。政府對癌症研究的大量資助和投資也進一步推動了市場成長。

癌症和腫瘤分析市場趨勢

癌症發生率上升

全球癌症發生率的不斷攀升是推動這一成長的主要動力。隨著癌症發生率達到峰值，以及人們對精準、特異性診斷方案的日益關注（以改善患者預後），對先進腫瘤分析技術的需求也逐年成長。根據美國癌症協會統計，2022年全球約有2,000萬例癌症確診病例，造成970萬人死亡。這一令人擔憂的趨勢凸顯了對更佳診斷和治療方法方案的迫切需求。此外，人口老化、生活方式改變和環境影響等因素表明，到2050年，癌症患者人數可能達到3,500萬人。這些數據表明，腫瘤分析在癌症治療中發揮著至關重要的作用，它能夠滿足個人化治療方法的需求，並提高患者的存活率。

基因組學和精準醫學的進展

基因組技術的進步，包括新一代定序（NGS）和蛋白質體學，徹底改變了癌症的研究和治療流程。正因如此，腫瘤分析市場正以驚人的速度成長。這些先進技術能夠進行全面的腫瘤分析，從而基於個別患者的基因組成開發個人化療法。治療效果不斷提升，為癌症患者提供精準治療變得日益重要。報告顯示，2022年全球癌症治療投資金額達約1,960億美元，過去五年平均年增率約12%。隨著對創新診斷和治療方法的需求不斷成長，先進的基因組技術在腫瘤分析中的應用也不斷擴大。這些發展正在改變腫瘤學領域，並為更有效、更具針對性的癌症治療鋪平道路，從而提振癌症和腫瘤分析市場的前景。

政府和研究經費

對癌症和精準醫療的投資和資金投入顯著增加，這也推動了腫瘤譜分析的發展。各國政府、製藥公司和其他研究機構正在合作開發更先進的譜分析解決方案，加速癌症早期診斷和治療方法的進步。英國癌症研究中心的報告顯示，英國政府承諾2027年將研發總投入提高到GDP的2.4%。這些項目表明，英國越來越重視癌症診斷和治療的創新，從而推動了癌症和腫瘤譜分析市場的需求。這些投資不僅使精準醫療更加普及，而且還促進了個人化癌症治療領域的突破性創新，從而推動了市場成長。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 二手資訊
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：全球癌症與腫瘤分析市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依癌症類型分類

  • 乳癌
  • 肺癌
  • 結腸癌
  • 攝護腺癌
  • 惡性黑色素瘤
  • 其他

第7章 市場區隔：依技術分類

  • 下一代定序（NGS）
  • 聚合酵素鏈鎖反應（PCR）
  • 免疫組織化學（IHC）
  • 原位雜合反應（ISH）
  • 微陣列
  • 其他

第8章 市場區隔：依方法

  • 基因組學
  • 蛋白質體學
  • 表觀遺傳學
  • 代謝體學

第9章 市場區隔：依應用領域分類

  • 個人化醫療
  • 診斷
  • 生物標記發現
  • 預後
  • 其他

第10章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第11章 SWOT 分析

第12章：價值鏈分析

第13章：波特五力分析

第14章：價格分析

第15章 競爭格局

  • 市場結構
  • 大公司
  • 主要公司簡介
    • Abbott Laboratories
    • Becton Dickinson and Company
    • Caris Life Sciences
    • Exact Sciences Corporation
    • F. Hoffmann-La Roche Ltd
    • Hologic Inc.
    • HTG Molecular Diagnostics Inc.
    • Illumina Inc.
    • Laboratory Corporation of America Holdings
    • NeoGenomics Laboratories
    • Qiagen NV
    • Siemens AG
    • Sysmex Corporation
Product Code: SR112026A5231

The global cancer/tumor profiling market size was valued at USD 13.5 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 27.3 Billion by 2034, exhibiting a CAGR of 7.89% during 2026-2034. North America currently dominates the market, holding a significant market share of over 42.8% in 2025. The market is experiencing significant growth driven by advancements in precision medicine, rising cancer prevalence and increasing adoption of personalized treatment approaches. Growing demand for biomarker-based diagnostics coupled with technological innovations in genomic and proteomic profiling, further fuels market expansion.

The cancer/tumor profiling market is driven by advancements in genomic and proteomic technologies enabling precise molecular diagnostics. Increasing prevalence of cancer globally coupled with the rising demand for personalized medicine accelerates cancer/tumor profiling market growth. For instance, in December 2024, Aster DM Healthcare announced the launch three initiatives Precision Oncology Clinics, the Aster Cancer Grid and Onco Collect during the Aster Cancer Conclave. These programs aim to enhance personalized data-driven cancer care through genomic approaches promote collaborative research and improve patient outcomes positioning India as a leader in innovative cancer treatment. Government funding and private investments in oncology research also play a pivotal role. Next-generation sequencing (NGS) and biomarker discovery are becoming increasingly adopted for early detection and targeted therapies while technological innovations in liquid biopsy improve profiling accuracy and enhance market expansion.

The United States cancer/tumor profiling market is driven by the high prevalence of cancer and the increasing demand for personalized medicine. According to the data published by the National Library of Medicine, in 2024 an estimated 2,001,140 new cancer cases and 611,720 deaths are projected in the U.S. Advancements in genomic and proteomic technologies such as next-generation sequencing (NGS) enhance the accuracy of tumor profiling. Substantial government funding and investments in oncology research further support market growth.

CANCER/TUMOR PROFILING MARKET TRENDS:

Rising Prevalence of Cancer

The increasing prevalence of cancer in the world has provided a considerable thrust to this growth. Cancer incidence is at its peak, as with an ever-growing focus on exact and specific diagnosis solutions towards the betterment of patient results, the necessity of advanced methods for tumor profiling keeps increasing every year. The American Cancer Society reported that nearly 20 million cases of cancer were diagnosed worldwide in 2022, resulting in 9.7 million deaths due to the disease. This concerning trend highlights the urgent need for better diagnostic and treatment options. Additionally, it is projected that the number of cancer cases could rise to 35 million by 2050, driven by factors such as an aging population, lifestyle changes, and environmental impacts. These statistics point out how tumor profiling plays an increasingly pivotal role in serving the needs for tailored therapies and improved survival in cancer care.

Advancements in Genomics and Precision Medicine

Advances in genomic technologies, including NGS and proteomics, have revolutionized the study of cancer and treatment processes. It is because of this that growth in the tumor profiling market has taken a massive pace. With such advanced technologies, comprehensive tumor profiling is achieved that leads to developing personalized therapies on the basis of the genetic make-up of each individual patient. The results of treatment are improving, and there is a greater emphasis on providing precise care for cancer patients. Reports indicate that global investments in cancer medicine totaled around USD 196 billion in 2022, with an average growth rate of approximately 12% over the last five years. The growing requirement for innovative diagnostics and therapeutic applications has led to an increased utilization of advanced genomic technologies for profiling tumors. These developments are creating positive cancer/tumor profiling market outlook by changing the oncology landscape, opening the way for more effective and targeted cancer treatments.

Government and Research Funding

Investment and funding for cancer and precision medicine are growing largely and thus boosting tumor profiling. The governments, pharmaceutical companies, and other research organizations collaborate on the development of more advanced profiling solutions, which speed up the advancement in early diagnosis and treatment methods for cancer. The UK Government has committed to increasing its total investment in research and development (R&D) to 2.4% of GDP by the year 2027, as reported by Cancer Research UK. Such programs underscore the growing focus on innovation in cancer diagnostics and treatments, which drives cancer/tumor profiling market demand. These investments do not only make precision medicine more accessible but also fuel breakthrough innovations in the personalized treatment of cancer, thereby fueling the market growth.

CANCER/TUMOR PROFILING INDUSTRY SEGMENTATION:

Analysis by Cancer Type:

  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Melanoma Cancer
  • Others

Breast cancer leads the cancer/tumor profiling market due to its high global prevalence and the increasing adoption of personalized medicine in oncology. Advanced profiling techniques such as next-generation sequencing (NGS) and immunohistochemistry (IHC) play a crucial role in identifying biomarkers for targeted therapies improving patient outcomes. The growing focus on early detection coupled with the rising availability of breast cancer-specific diagnostic tests and therapies drives market growth. Continuous research efforts and clinical trials further strengthen breast cancer's leadership in this sector.

Analysis by Technology:

  • Next-Generation Sequencing (NGS)
  • Polymerase Chain Reaction (PCR)
  • Immunohistochemistry (IHC)
  • In-Situ Hybridization (ISH)
  • Microarray
  • Others

NGS is one of the most prominent technologies in the cancer/tumor profiling market which enables the comprehensive genomic analysis for identifying cancer mutations and biomarkers. Its high-throughput capability and precision facilitate personalized treatments and diagnostics. Increasing adoption of NGS in clinical oncology and its application in targeted therapies and companion diagnostics significantly drive its demand in cancer profiling research.

PCR is highly used in cancer/tumor profiling because of its high sensitivity and specificity in detecting genetic mutations and alterations. It is also very important in the analysis of minimal DNA samples which makes it ideal for early cancer detection. The advancements in real-time and digital PCR further enhance its utility which has fostered its growth as a critical technology in oncology diagnostics.

IHC is one of the core technologies used to identify the tumor's specific protein and biomarkers profiles. This method's usefulness in finding hormone receptors status for example in breast cancer is confirmed by determining the expression of HER2 in cancer. IHC supports personalized treatment approaches through the selection of targeted therapies by a clinician based on biomarker expression patterns.

ISH technology is also used for cancer profiling. This technology can accurately visualize genetic abnormalities directly in tissue samples. It is highly efficient in detecting gene amplifications, translocations and deletions. Applications include the identification of HER2/neu in breast cancer and other chromosomal aberrations. Its use is continuously propelled by the rising demand for accurate molecular diagnostics.

Microarray technology supports cancer profiling by analyzing gene expression patterns and identifying biomarkers associated with tumor development. It enables large-scale screening of genetic data providing insights into cancer classification and progression. The utility of the technology in discovering therapeutic targets and stratifying patients for clinical trials makes it a valuable tool in oncology research and diagnostics.

Analysis by Technique:

  • Genomics
  • Proteomics
  • Epigenetics
  • Metabolomics

Genomics leads the market with around 39.8% of cancer/tumor profiling market share in 2025. Genomics is the largest technique in the cancer/tumor profiling market because it plays a central role in understanding the genetic basis of cancer. Genomic profiling allows for the identification of mutations, gene expression patterns and biomarkers critical for personalized oncology. Technologies such as next-generation sequencing (NGS) and microarrays drive this segment by offering high-throughput and precise analyses. The rise in targeted therapies advancements in companion diagnostics and the increasing adoption of genomics within clinical oncology heighten its presence further while promoting successful treatment outcomes and new areas for research.

Analysis by Application:

  • Personalized Medicine
  • Diagnostics
  • Biomarker Discovery
  • Prognostics
  • Others

The personalized medicine segment is highly important in the cancer/tumor profiling market as it provides for treatment based on an individual's genetic and molecular profile. This improves the effectiveness of therapy while minimizing side effects targeting the specific biomarkers. Increasing precision oncology adoption and advancement in tumor profiling techniques propel this segment's growth significantly which also enhances patient outcomes.

The market is dominated by the diagnostics segment mainly because of the accurate type and stage of cancer identification via advanced tumour profiling techniques. Technologies such as PCR, NGS and IHC enable early diagnosis and improved decision-making in treatment plans. The demand for early screening of cancer and non-invasive diagnostic solutions is therefore driving further expansion in this critical application area.

Biomarker discovery is one of the key applications of cancer profiling focused on identifying molecular markers associated with cancer development and progression. This helps in targeted drug development and companion diagnostics that drive the evolution of precision medicine. Continuous genomics and proteomics research coupled with increased investments in oncology studies propel this segment in the market.

The prognostics segment is used to predict the progression of cancer, survival rate of patients and possible treatment response through tumor profiling. It supports the planning of treatment on an individual basis by analyzing genetic mutations and biomarkers. Rising awareness of the benefits of prognostic tools and advancements in molecular diagnostics contribute to the growing adoption of prognostic applications in the cancer/tumor profiling market.

Regional Analysis:

  • North America
    • United States
    • Canada
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

In 2025, North America accounted for the largest market share of over 42.8%. North America dominates the cancer/tumor profiling market with the region witnessing an advanced healthcare infrastructure, high adoption of precision medicine and substantial investments in oncology research. The region benefits from the widespread availability of advanced diagnostic technologies such as NGS and PCR along with a strong presence of key market players. Rising cancer prevalence and government initiatives to support cancer screening and biomarker research further propel market growth. With higher clinical trials and research collaborations among research institutes North America leads this market.

KEY REGIONAL TAKEAWAYS:

UNITED STATES CANCER/TUMOR PROFILING MARKET ANALYSIS

In 2025, the United States captured 88.9% of revenue in the North American market. The American Cancer Society anticipates more than 1.9 million new cancer cases in the U.S. for 2024. It's estimated that 1 in 23 men and 1 in 24 women will be diagnosed with colorectal cancer at some point in their lives. Current projections for 2023 suggest that there will be 106,970 new cases of colon cancer and 46,050 new cases of rectal cancer in the U.S. With this trend in cancer, growing need is being seen to develop diagnostic and prognostic tools at more advanced levels such as tumor profiling. Tumor profiling provides more informative molecular data which helps identify mutations, biomarkers, and targets of therapy. As healthcare systems look to the earlier diagnosis and tailoring of therapy to improve outcomes in patients there will be immense opportunities for the growth of the cancer/tumor profiling market.

EUROPE CANCER/TUMOR PROFILING MARKET ANALYSIS

The Europe cancer/tumor profiling market is experiencing significant growth driven by the rising burden of cancer particularly due to an ageing population. From 2010 to 2020, the European population living with cancer saw an annual increase of 3.5% leading to an overall rise of 41% according to the EU Science Hub. With the aging population the prevalence of cancer is anticipated to grow which will increase the need for advanced diagnostic technologies such as tumor profiling. These technologies such as next-generation sequencing (NGS) and liquid biopsy enable early cancer detection and personalized treatment strategies improving patient outcomes. With an increased focus on precision medicine and the growing recognition of the benefits of early and accurate cancer detection Europe is seeing an uptick in the adoption of tumor profiling solutions. Additionally, the region's strong healthcare infrastructure and government support for cancer research are expected to continue driving market expansion in the coming years.

ASIA PACIFIC CANCER/TUMOR PROFILING MARKET ANALYSIS

The Asia Pacific region experiences a considerable burden from cancer with the five most prevalent types being lung cancer (1,315,136 new cases), breast cancer (1,026,171 cases), colorectal cancer (1,009,400 cases), stomach cancer (819,944 cases) and liver cancer (656,992 cases) as reported by NIH data. This rising incidence is fueling the demand for advanced cancer diagnostics including tumor profiling technologies like next-generation sequencing (NGS) and liquid biopsy. As healthcare infrastructure improves across countries like China, India and Japan there is a strong push for precision medicine and personalized therapies. These innovations are driving the adoption of tumor profiling tools to enhance early detection, guide treatment decisions and improve patient outcomes. Government initiatives, increased healthcare spending and strategic partnerships with global biotech and pharmaceutical firms are accelerating the adoption of these technologies in the region. The Asia Pacific cancer/tumor profiling market is poised for significant growth driven by the need for more effective tailored cancer care solutions.

LATIN AMERICA CANCER/TUMOR PROFILING MARKET ANALYSIS

As cited by the ESMO 2022 report Latin America presents a significant burden of cancer. An estimated 1.5 million new cases and 700,000 deaths are reported yearly. The cancer incidence and mortality rates in this region stand at 186.5 and 86.6 per 100,000, indicating a pressing requirement for advanced diagnostic solutions. Cancer has recently been a new tool for tackling cancer by way of personalising the treatment processes to suit every patient's specific genetic makeup. This, besides enhancing patient results, has managed to tackle cancer mortality rates across the region. Governments in Latin America are pouring more investments in healthcare infrastructure; the emphasis lies on early detection and precision medicine to curb rising cancer burdens. The innovation in diagnostic techniques is driven by collaborations between regional healthcare providers and global biotechnology firms, increasing access to next-generation sequencing and other tumor profiling technologies. Such efforts are expected to fuel the growth of the tumor profiling market, bringing hope for better cancer management across the region.

MIDDLE EAST AND AFRICA CANCER/TUMOR PROFILING MARKET ANALYSIS

The Middle East and Africa (MEA) region is undergoing a significant change in the increasing number of cancer cases. Ingestion of lifestyle changes, aging populations, and a burgeoning environmental risk factor are widespread. Cancer incidence is projected to increase 1.8-fold by 2030 in Arab countries, according to the NIH, further necessitating advanced diagnostic and treatment solutions. The demand for cancer/tumor profiling is accelerating as healthcare systems in the region focus on early detection and personalized treatment approaches to improve patient outcomes. Governments and private organizations are increasingly investing in healthcare infrastructure, research initiatives, and collaborations with global biotechnology companies to bring state-of-the-art technologies, such as next-generation sequencing (NGS) and liquid biopsy solutions, to the region. It can be attributed to the presence of initiatives like UAE National Cancer Registry and healthcare targets set in Saudi Arabia through its Vision 2030, leading to an advance in cancer profiling. This, too, will foster growth for the MEA market on cancer/tumor profiling.

COMPETITIVE LANDSCAPE:

The cancer/tumor profiling market is highly competitive with key players focusing on innovation, strategic partnerships and product development to strengthen their market presence. Leading companies are driving advancements in genomic and molecular diagnostics. These firms invest heavily in research and development to introduce advanced profiling technologies such as NGS and biomarker-based diagnostics. Additionally, collaborations between biotechnology companies, research institutions and healthcare providers are fueling market expansion. Emerging players are also leveraging technological advancements and targeting niche segments to gain a competitive edge further intensifying the market's dynamic landscape.

The report provides a comprehensive analysis of the competitive landscape in the cancer tumor profiling market with detailed profiles of all major companies, including:

  • Abbott Laboratories
  • Becton Dickinson and Company
  • Caris Life Sciences
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd
  • Hologic Inc.
  • HTG Molecular Diagnostics Inc.
  • Illumina Inc.
  • Laboratory Corporation of America Holdings
  • NeoGenomics Laboratories
  • Qiagen N.V.
  • Siemens AG
  • Sysmex Corporation

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Cancer/Tumor Profiling Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Cancer Type

  • 6.1 Breast Cancer
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Lung Cancer
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Colorectal Cancer
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Prostate Cancer
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Melanoma Cancer
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Others
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast

7 Market Breakup by Technology

  • 7.1 Next-Generation Sequencing (NGS)
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Polymerase Chain Reaction (PCR)
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Immunohistochemistry (IHC)
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 In-Situ Hybridization (ISH)
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Microarray
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Others
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast

8 Market Breakup by Technique

  • 8.1 Genomics
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Proteomics
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Epigenetics
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Metabolomics
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Application

  • 9.1 Personalized Medicine
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Diagnostics
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Biomarker Discovery
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Prognostics
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast
  • 9.5 Others
    • 9.5.1 Market Trends
    • 9.5.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Abbott Laboratories
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Becton Dickinson and Company
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 Caris Life Sciences
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
    • 15.3.4 Exact Sciences Corporation
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 F. Hoffmann-La Roche Ltd
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
    • 15.3.6 Hologic Inc.
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 HTG Molecular Diagnostics Inc.
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
    • 15.3.8 Illumina Inc.
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Laboratory Corporation of America Holdings
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 NeoGenomics Laboratories
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
    • 15.3.11 Qiagen N.V.
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis
    • 15.3.12 Siemens AG
      • 15.3.12.1 Company Overview
      • 15.3.12.2 Product Portfolio
      • 15.3.12.3 Financials
      • 15.3.12.4 SWOT Analysis
    • 15.3.13 Sysmex Corporation
      • 15.3.13.1 Company Overview
      • 15.3.13.2 Product Portfolio
      • 15.3.13.3 Financials
      • 15.3.13.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Cancer/Tumor Profiling Market: Major Drivers and Challenges
  • Figure 2: Global: Cancer/Tumor Profiling Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Cancer/Tumor Profiling Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 4: Global: Cancer/Tumor Profiling Market: Breakup by Cancer Type (in %), 2025
  • Figure 5: Global: Cancer/Tumor Profiling Market: Breakup by Technology (in %), 2025
  • Figure 6: Global: Cancer/Tumor Profiling Market: Breakup by Technique (in %), 2025
  • Figure 7: Global: Cancer/Tumor Profiling Market: Breakup by Application (in %), 2025
  • Figure 8: Global: Cancer/Tumor Profiling Market: Breakup by Region (in %), 2025
  • Figure 9: Global: Cancer/Tumor Profiling (Breast Cancer) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 10: Global: Cancer/Tumor Profiling (Breast Cancer) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 11: Global: Cancer/Tumor Profiling (Lung Cancer) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 12: Global: Cancer/Tumor Profiling (Lung Cancer) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 13: Global: Cancer/Tumor Profiling (Colorectal Cancer) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 14: Global: Cancer/Tumor Profiling (Colorectal Cancer) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 15: Global: Cancer/Tumor Profiling (Prostate Cancer) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 16: Global: Cancer/Tumor Profiling (Prostate Cancer) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 17: Global: Cancer/Tumor Profiling (Melanoma Cancer) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 18: Global: Cancer/Tumor Profiling (Melanoma Cancer) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 19: Global: Cancer/Tumor Profiling (Other Cancer Types) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 20: Global: Cancer/Tumor Profiling (Other Cancer Types) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 21: Global: Cancer/Tumor Profiling (Next-Generation Sequencing-NGS) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 22: Global: Cancer/Tumor Profiling (Next-Generation Sequencing-NGS) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 23: Global: Cancer/Tumor Profiling (Polymerase Chain Reaction-PCR) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 24: Global: Cancer/Tumor Profiling (Polymerase Chain Reaction-PCR) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 25: Global: Cancer/Tumor Profiling (Immunohistochemistry-IHC) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 26: Global: Cancer/Tumor Profiling (Immunohistochemistry-IHC) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 27: Global: Cancer/Tumor Profiling (In-Situ Hybridization-ISH) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 28: Global: Cancer/Tumor Profiling (In-Situ Hybridization-ISH) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 29: Global: Cancer/Tumor Profiling (Microarray) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 30: Global: Cancer/Tumor Profiling (Microarray) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 31: Global: Cancer/Tumor Profiling (Other Technologies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 32: Global: Cancer/Tumor Profiling (Other Technologies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 33: Global: Cancer/Tumor Profiling (Genomics) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 34: Global: Cancer/Tumor Profiling (Genomics) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 35: Global: Cancer/Tumor Profiling (Proteomics) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 36: Global: Cancer/Tumor Profiling (Proteomics) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 37: Global: Cancer/Tumor Profiling (Epigenetics) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 38: Global: Cancer/Tumor Profiling (Epigenetics) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 39: Global: Cancer/Tumor Profiling (Metabolomics) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 40: Global: Cancer/Tumor Profiling (Metabolomics) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 41: Global: Cancer/Tumor Profiling (Personalized Medicine) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 42: Global: Cancer/Tumor Profiling (Personalized Medicine) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 43: Global: Cancer/Tumor Profiling (Diagnostics) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 44: Global: Cancer/Tumor Profiling (Diagnostics) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 45: Global: Cancer/Tumor Profiling (Biomarker Discovery) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 46: Global: Cancer/Tumor Profiling (Biomarker Discovery) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 47: Global: Cancer/Tumor Profiling (Prognostics) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 48: Global: Cancer/Tumor Profiling (Prognostics) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 49: Global: Cancer/Tumor Profiling (Other Applications) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 50: Global: Cancer/Tumor Profiling (Other Applications) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 51: North America: Cancer/Tumor Profiling Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 52: North America: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 53: United States: Cancer/Tumor Profiling Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 54: United States: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 55: Canada: Cancer/Tumor Profiling Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 56: Canada: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 57: Asia-Pacific: Cancer/Tumor Profiling Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 58: Asia-Pacific: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 59: China: Cancer/Tumor Profiling Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 60: China: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 61: Japan: Cancer/Tumor Profiling Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 62: Japan: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 63: India: Cancer/Tumor Profiling Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 64: India: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 65: South Korea: Cancer/Tumor Profiling Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 66: South Korea: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 67: Australia: Cancer/Tumor Profiling Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 68: Australia: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 69: Indonesia: Cancer/Tumor Profiling Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 70: Indonesia: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 71: Others: Cancer/Tumor Profiling Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 72: Others: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 73: Europe: Cancer/Tumor Profiling Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 74: Europe: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 75: Germany: Cancer/Tumor Profiling Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 76: Germany: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 77: France: Cancer/Tumor Profiling Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 78: France: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 79: United Kingdom: Cancer/Tumor Profiling Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 80: United Kingdom: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 81: Italy: Cancer/Tumor Profiling Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 82: Italy: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 83: Spain: Cancer/Tumor Profiling Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 84: Spain: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 85: Russia: Cancer/Tumor Profiling Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 86: Russia: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 87: Others: Cancer/Tumor Profiling Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 88: Others: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 89: Latin America: Cancer/Tumor Profiling Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 90: Latin America: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 91: Brazil: Cancer/Tumor Profiling Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 92: Brazil: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 93: Mexico: Cancer/Tumor Profiling Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 94: Mexico: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 95: Others: Cancer/Tumor Profiling Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 96: Others: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 97: Middle East and Africa: Cancer/Tumor Profiling Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 98: Middle East and Africa: Cancer/Tumor Profiling Market: Breakup by Country (in %), 2025
  • Figure 99: Middle East and Africa: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 100: Global: Cancer/Tumor Profiling Industry: SWOT Analysis
  • Figure 101: Global: Cancer/Tumor Profiling Industry: Value Chain Analysis
  • Figure 102: Global: Cancer/Tumor Profiling Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Cancer/Tumor Profiling Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Cancer/Tumor Profiling Market Forecast: Breakup by Cancer Type (in Million USD), 2026-2034
  • Table 3: Global: Cancer/Tumor Profiling Market Forecast: Breakup by Technology (in Million USD), 2026-2034
  • Table 4: Global: Cancer/Tumor Profiling Market Forecast: Breakup by Technique (in Million USD), 2026-2034
  • Table 5: Global: Cancer/Tumor Profiling Market Forecast: Breakup by Application (in Million USD), 2026-2034
  • Table 6: Global: Cancer/Tumor Profiling Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 7: Global: Cancer/Tumor Profiling Market: Competitive Structure
  • Table 8: Global: Cancer/Tumor Profiling Market: Key Players